Chromocell Plans to Shine at Upcoming Conferences
Chromocell Therapeutics Corporation, a trailblazer in the field of non-opioid pain treatment, is all set to make waves in the investment community with upcoming presentations. Frank Knuettel II, the company’s CEO, is slated to speak at two prominent investor conferences, showcasing Chromocell’s commitment to providing innovative solutions in pain management.
Investor Engagement at LDMicro Main Event XVII
The first notable event is the LDMicro Main Event XVII, taking place over several days. This significant conference is not only a gathering for micro-cap companies but also a platform for investors to discover the latest developments in the industry. Chromocell is scheduled to present on October 29, 2024, from 10:00 AM to 10:25 AM PT at the Luxe Sunset Boulevard Hotel.
Event Details and Registration
Registration for both in-person attendance and virtual options is available, empowering investors to connect more deeply with the company. The event has long been recognized as a gold standard in the micro-cap space, promoting emerging businesses and offering intricate insights into their potential.
Discussion at Spartan Capital Investor Conference
Following the LDMicro event, the Spartan Capital Investor Conference is another important venue for Chromocell. Scheduled for November 4, 2024, from 9:45 AM to 10:00 AM ET at The Pierre Hotel in New York City, this conference aims to bring together industry leaders and institutional investors.
Networking Opportunities
This conference offers unique networking opportunities for executives, institutional investors, and thought leaders in the U.S. capital markets. It's a prime chance for Chromocell to engage with stakeholders and unveil their innovative approaches to pain relief.
About Chromocell Therapeutics Corporation
Chromocell Therapeutics Corporation specializes in developing and commercializing cutting-edge therapeutics aimed at chronic pain. The company's innovative solutions focus on non-opioid treatments, particularly targeting the sodium ion-channel NaV1.7. Their mission is to redefine pain management through non-addictive solutions that prioritize patient safety and well-being.
Innovation in Non-Opioid Pain Management
By concentrating on neuropathic and eye pain, Chromocell is shaping the future of pain relief, striving for effective solutions without the risks associated with traditional opioid therapies. To learn more about their pioneering work and ongoing projects, interested parties can visit their website or follow them on social media.
Frequently Asked Questions
What is Chromocell Corporation focused on?
Chromocell Therapeutics Corporation develops non-opioid, non-addictive therapeutics aimed at alleviating various forms of pain.
When is the LDMicro Main Event XVII conference?
The LDMicro Main Event XVII occurs from October 28 to 30, 2024, with Chromocell presenting on October 29.
Where will the Spartan Capital Investor Conference be held?
The Spartan Capital Investor Conference will take place at The Pierre Hotel in New York City on November 4, 2024.
Who is presenting for Chromocell?
Frank Knuettel II, the CEO of Chromocell Therapeutics Corporation, will be the presenter at both conferences.
How can investors stay updated about Chromocell?
Investors can learn more about Chromocell by visiting their official website or following them on social media platforms for the latest updates and information.
